Education
About Us
Working with TipRanks
Follow Us
Liquidia Technologies Inc (LQDA)
NASDAQ:LQDA
LQDA Stock Chart & Stats
$37.93
<$0.01(<0.01%)
At close: 4:00 PM EST
$37.93
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$11.26 - $41.57
Previous CloseN/A
Volume97.81K
Average Volume (3M)1.53M
Market Cap
$3.30B
Enterprise Value$2.00B
Total Cash (Recent Filing)$157.50M
Total Debt (Recent Filing)$199.18M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Mar 12, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding86,995,480
10 Day Avg. Volume2,734,357
30 Day Avg. Volume1,525,936
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)11.98
Price to Sales (P/S)66.13
P/FCF Ratio-9.41
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue28.97
Enterprise Value/Gross Profit32.40
Enterprise Value/Ebitda-20.36
Forecast
1Y Price Target
$48.75Price Target Upside28.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)2
Revenue Forecast (FY)$478.85M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionStrong early patient adoption and a growing prescriber base indicate accelerating Yutrepia uptake, supporting potential revenue expansion as market penetration increases.
Market Access And ProfitabilityContracts with major commercial payers combined with early operating profitability reduce near-term financing risk and improve access, which could broaden the investor base and support valuation.
Product PipelineAdvancement of next-generation therapy L606 and a randomized Phase 3 program can extend long-term revenue potential by adding a second clinically differentiated asset within the pulmonary-hypertension treatment landscape.
Bears Say
Clinical Readout TimingUnclear timing for planned study data readouts increases uncertainty about when clinical results might act as meaningful stock catalysts.
Patent Litigation RiskPending patent infringement litigation and the risk of an adverse ruling create material downside risk that could limit market exclusivity and disrupt sales continuity.
Sales VisibilitySeasonal and specialty-pharmacy ordering patterns can create variability in patient starts and prescriptions, reducing short-term sales visibility and complicating revenue forecasting.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $11.26 and its highest was $41.57 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $3.30B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Mar 12, 2026 which is in 52 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Nov 03, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.389 by $0.349.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Undervalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.19.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 86,995,480 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.389. Following the earnings report the stock price went up 3.53%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.75 (28.53% Upside)
$48.75 (28.53% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
203.19%
12-Months-Change
Fundamentals
Return on Equity
-183.82%
Trailing 12-Months
Asset Growth
9.13%
Trailing 12-Months
Company Description
Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Liquidia has experienced a strong launch and financial performance with YUTREPIA, achieving significant prescription uptake and positive cash flow. However, the ongoing net loss and litigation uncertainty present challenges that could impact future performance.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$48.75
▲(28.53% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
22.66% Insiders
7.35% Mutual Funds
0.21% Other Institutional Investors
60.24% Public Companies and Individual Investors